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Background/aim: Acinetobacter baumannii (A. baumannii) is one of the most common healthcare-associated infectious agents
worldwide. The aim of this study was to investigate the in vitro synergistic activities of several antibiotic combinations against
carbapenem-resistant (CR) A. baumannii isolates.
Materials and methods: Eighteen CR A. baumannii strains were isolated from the patients who were hospitalized in the intensive care
unit between June 2012 and August 2012. The in vitro effects of single and binary combinations of meropenem (MEM), colistin (CST),
tigecycline (TGC), and sulbactam (SUL) on these isolates were determined using the Epsilometer test (E-test) method.
Results: All 18 isolates were resistant to MEM and SUL and susceptible to CST. TGC was detected as susceptible in two of the isolates and
intermediate susceptibility results were observed in the remaining isolates. With MEM-CST and MEM-TGC combinations, synergism
was determined against all isolates. The synergistic and/or additive effect ratios were detected in MEM-SUL, CST-SUL, TGC-SUL, and
CST-TGC combinations as 16.7%, 38.9%, 16.7%, and 5.6%, respectively.
Conclusion: Among the tested antimicrobial combinations, the in vitro combination of MEM with TGC or CST was most effective
against the CR A. baumannii strains.
Key words: Acinetobacter baumannii, drug resistance, synergy test, E-test method

1. Introduction
Acinetobacter baumannii (A.baumannii) has emerged
as an important pathogen that can cause outbreaks in
intensive care units (1). Its ability to acquire resistance
to many antibiotic classes and to maintain its vitality on
nonviable and dry surfaces for long periods of time makes
it clinically significant. Carbapenems, sulbactam (SUL),
tigecycline (TGC), and colistin (CST) are antibiotics whose
activities have been proven against Acinetobacter spp.induced infections. However, resistance of Acinetobacter
strains against antibiotics has been increasingly reported
worldwide (2).
Due to the high morbidity and mortality rates of
severe A. baumannii infections, combination therapies, as
opposed to monotherapy, are suggested (3). A synergistic
effect may be developed when antibiotics are used in
combination. Through this synergistic effect, treatment
efficacy can be improved and resistance can be prevented
(4). In vitro synergy tests can reveal combination therapies
* Correspondence: drsevimyavas@gmail.com
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that can be used to treat carbapenem-resistant (CR) A.
baumannii infections (5). Three methods to detect in
vitro synergy have been described: the time-kill assay,
checkerboard, and the Epsilometer test (E-test) method.
The E-test method is simple to use and time efficient (6).
The primary objective of this study was to determine the
in vitro synergistic activities of meropenem (MEM), CST,
TGC, and SUL in binary combinations using the E-test
method against CR A. baumannii isolates. The secondary
objectives were: contributing to the development of new
therapy protocols and decreasing the development of
antibiotic resistance.
2. Materials and methods
2.1. Microorganisms
A total of 18 CR A. baumannii isolates, including
carbapenem resistance, were included in this prospective
study. These isolates were evaluated with VITEK 2
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(bioMérieux S.A., Craponne, France) for antibiotic
susceptibility and resistance pattern and identifications
at the species level. All bacteria were isolated from the
endotracheal aspirates of individual patients in whom
ventilator associated pneumonia was detected between
June 2012 and August 2012 at Ankara Numune Research
and Training Hospital in Ankara, Turkey.
2.2. Antimicrobial agents
The meropenem, colistin, tigecycline, and sulbactam
E-test (bioMérieux S.A.) were utilized.
2.3. Minimum inhibitory concentration (MIC)
determination and synergy test
In our study, the E-test method was used to determine the
single MIC values of MEM, CST, TGC, and SUL. We also
used it to determine the effects of the binary combination
of these antibiotics against 18 A. baumannii isolates in a
synergy test. The MIC values of the selected antimicrobial
agents were detected separately and their fractional
inhibitory concentrations (FIC) were calculated to allow
for an interpretation (i.e. synergism) (7). For each of the
18 isolates, the single MIC values of A and B antibiotics in
binary combination were determined.
According to the Clinical and Laboratory Standards
Institute (CLSI) antibiotic susceptibility standards, for
Acinetobacter spp., if the MEM MIC is ≤4 µg/mL, then it
is accepted as susceptible (S); if it is 8 µg/mL, then it is
accepted as intermediately susceptible (IM); and if it is ≥16
µg/mL, then it is accepted as resistant (R). If the CST MIC
is ≤2 µg/mL, then it is accepted as susceptible (S) and if it is
≥4 µg/mL, then it is accepted as resistant (R). Due to lack of
reference values for single SUL, an adaptation was made by
taking the MIC ranges (≤8/4 susceptible; 16/8 intermediate
susceptible; and ≥32/16 resistant) specified for SUL in the
ampicillin-sulbactam combination as a reference in the
CLSI guideline, according to other studies in the literature
(8–10). For the MIC values of TGC against Acinetobacter
spp, as in many studies, the standards specified for the
Enterobacteriaceae family by the U.S. Food and Drug
Administration were used. According to these standards,
if the MIC reference values of TGC are MIC ≤ 2 µg/mL,
then it is accepted as susceptible (S); if MIC is >2 < 8, then
it is accepted as intermediate susceptible (IM); and if it is ≥
8 µg/mL, then it is accepted as resistant (R) (11–13).
In our study, the E-test prediffusion method was
used as a synergy test method, which was also utilized in
previously published studies (6,14,15).
The fractional inhibitory concentration (FIC) index
(Σ FIC) was calculated using the following formula to
determine the efficacy of the combination.
The MIC numerical value of [A] in the presence of [B],
FIC [A] = ——————————————.
The MIC numerical value of the single [A],
The MIC numerical value of [B] in the presence of [A],

FIC [B] = ——————————————.
MIC numerical value of the single [B],
Σ FIC index = FIC [A] + FIC [B].
If Σ FIC ≤ 0.5, then it is considered synergistic.
If Σ FIC > 0.5 and ≤ 1, then it is considered additive.
If Σ FIC > 1 and ≤ 4, then it is considered indifferent.
If Σ FIC > 4, then it is considered antagonist (6,16).
Σ FIC values have been calculated for 6 different
antibiotic combinations (MEM-CST, MEM-TGC, MEMSUL, CST-TGC, CST-SUL, and TGC-SUL) using E-test
in 18 CR A. baumannii.
2.4. Statistics
The results obtained from the in vitro interactions of the
antibiotic combinations applied to 18 A. baumannii strains
were examined. The results were analyzed using SPSS; the
interactions in the antibiotics combinations were grouped
as the presence of synergistic and/or additive interactions
and the absence of any of the two interactions. In addition,
the statistical analysis was evaluated with McNemar’s test
in SPSS.
3. Results
According to the MIC values, all isolates were resistant to
MEM (MIC ≥ 32 µg/mL) and SUL (MIC 16–96 µg/mL);
however, all isolates were susceptible to CST (MIC 0.38–1
µg/mL). TGC was found to be sensitive in 2 of the isolates
(MIC 0.75/0.75 µg/mL), and intermediate susceptibility
results were observed for the remaining isolates (MIC 3–6
µg/mL). The ΣFIC values were calculated for six antibiotic
combinations (MEM-CST, MEM-TGC, MEM-SUL, CSTTGC, CST-SUL, and TGC-SUL), and their synergistic,
additive, indifferent, and antagonistic interactions are
shown in the Table. The synergistic effects between MEM
and CST and between MEM and TGC were detected
against all the tested microorganisms. Between CST and
TGC, antagonism was detected in two isolates, and an
indifferent effect was observed in the remaining isolates.
In seven isolates, an additive effect was observed for
the TGC-SUL combination. An additive effect was also
detected in two isolates for the MEM-SUL and TGCSUL combinations, and indifference was detected for the
remaining isolates.
3.1. Statistical comparison of antibiotic combinations in
terms of the synergistic effect
The rate of the presence of one synergistic and/or additive
interaction was greater in the MEM-CST and MEM-TGC
combinations compared with the CST-SUL, MEM-SUL,
and TGC-SUL combinations; this result was statistically
significant (P < 0.05).
4. Discussion
A. baumannii infections are difficult to treat and
combination antibiotics therapy is often required.
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Table. Results of antimicrobial synergistic activities for binary combinations of MEM-CST, MEM-TGC, MEM-SUL, CST-TGC, CSTSUL, and TGC-SUL.
MEM-CST

MEM-TGC

MEM-SUL

CST-TGC

CST-SUL

TGC-SUL

ΣFIC

ΣFIC

ΣFIC

ΣFIC

ΣFIC

ΣFIC

1

0.32

S

0.25

S

2.1

ID

5

AG

1.05

ID

2.05

ID

2

0.38

S

0.43

S

2.17

ID

4.33

AG

1.13

ID

1.41

ID

3

0.15

S

0.31

S

0.5

S

1.83

ID

0.6

ADD

1

ADD

4

0.23

S

0.44

S

1.13

ID

1.7

ID

1.45

ID

1.13

ID

5

0.5

S

0.23

S

2.1

ID

2.5

ID

1.06

ID

0.72

ADD

6

0.15

S

0.25

S

2.1

ID

1.58

ID

0.66

ADD

0.77

ADD

7

0.09

S

0.25

S

1.13

ID

1.7

ID

1

ADD

1.13

ID

8

0.1

S

0.32

S

0.85

ADD

2

ID

1

ADD

1.1

ID

9

0.2

S

0.25

S

1.13

ID

3.17

ID

1.35

ID

1.08

ID

10

0.14

S

0.23

S

1.75

ID

1.57

ID

1.35

ID

1.19

ID

11

0.27

S

0.23

S

1.69

ID

2.22

ID

1.34

ID

1.1

ID

12

0.18

S

0.28

S

10.6

AG

1.99

ID

1.33

ID

2

ID

13

0.32

S

0.25

S

1.63

ID

3.67

ID

1.06

ID

1.46

ID

14

0.16

S

0.25

S

1.13

ID

0.89

ADD

1

ADD

1.17

ID

15

0.25

S

0.19

S

0.58

ADD

1.33

ID

0.68

ADD

2

ID

16

0.2

S

0.27

S

1.63

ID

1.99

ID

1.35

ID

1.46

ID

17

0.2

S

0.5

S

1.13

ID

1.75

ID

1.5

ID

1.13

ID

18

0.27

S

0.38

S

2.13

ID

1.75

ID

1

ADD

1.06

ID

MEM: meropenem, CST: colistin, TGC: tigecycline, SUL: sulbactam, S: synergy, ID: indifference, ADD: additive, and AG: antagonism.

However, a definitive consensus on which combination
therapy is effective in the treatment of A. baumannii
infections is not available. In our study, we evaluated the
synergistic activity of different antimicrobial combinations
against CR A. baumannii isolates.
We examined the studies on this subject in the literature
to compare the results of our study. Sopirala et al. (16)
evaluated the activity of binary combinations of TGC,
CST, and imipenem (IPM) against 8 pan-drug resistant
A. baumannii isolates. The authors observed synergistic
activity in all isolates for the IPM-TGC and IPM-CST
combinations.
Similarly, Pongpech et al. (17) evaluated the activities of
binary combinations of MEM with CST, MEM with SUL,
and CST with SUL against 32 IPM- and MEM-resistant A.
baumannii isolates. The synergistic activity rates detected
by the authors in binary MEM-SUL and MEM-CST
combinations were 70% and 73.3%, respectively.
In a study by Pankey and Ashcraft (18), the synergy was
evaluated using the E-test method for the combination of
MEM with polymyxin B against 8 MEM-resistant clinical
A. baumannii isolates. The authors observed synergistic
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activity in five isolates for the combination of MEM with
polymyxin B.
In our study, synergistic activity was detected for the
MEM-CST and MEM-TGC combinations against strains
that we found to be resistant to MEM and moderately
susceptible to TGC, which is in line with the literature.
The results of our study and similar studies in the literature
indicate that the activity of MEM increases when it is used
with TGC and CST against MEM-resistant strains. This
result may be related to the bactericidal effect, as well as to
the fact that these drugs have different effect mechanisms.
The synergistic activity of the combination CST-TGC
was examined in our study. Indifference and antagonistic
activity were detected for the CST-TGC combination. In
a study by Tan et al. (19), 40% of isolates demonstrated
synergistic activity according to the combination of
polymyxin B and TGC against A. baumannii isolates. In
other studies evaluating the synergistic activity of the CST
and TGC combination, synergy and indifference were
reported, but no antagonistic effects were demonstrated
(16,20–22). Regarding the combination of CST with TGC,
some differences were found between our study results and
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other studies in the literature, most likely resulting from
the different methods used in the synergy tests. The E-test
prediffusion method was used in our study; however, other
studies have used variations of that method or different
methods entirely.
The synergistic activity of sulbactam with MEM, CST,
and TGC was also examined in our study, and indifferent
activity was observed. Based on the synergistic activity
of SUL with various other antibiotics in the literature,
synergistic, additive, and indifferent effects were detected
in some other studies (23–25). The differences between the
study results are based on the absence of a certain MIC value
specified by CLSI for SUL; therefore, there is uncertainty
concerning the acceptable limits of the measurements. In
addition, the SUL MIC values in the A. baumannii strains
included in the study have high values, such as 16–96 µg/
mL. These high MIC values may have affected these results.
Additionally, in our study, we sought to determine
the combination with which we could achieve the most
successful results for practical use by comparing the
activities of antimicrobial drug combinations for which
we have identified synergistic/additive activity. As a
result of these comparisons, the best in vitro synergistic
activity was achieved with the MEM-CST and MEM-TGC
combinations.

There were some disadvantages related to our study.
One great disadvantage was that all the isolates were
derived from the same hospital. In addition, the value of
the overall results could have been increased if we studied
a larger number of isolates. Another limitation of this study
was that the limited scale of the antibiotic concentration in
the E-test strips did not allow the recording of higher MIC
values. The absence of standardization in all synergy test
methods could be considered a limitation as well.
In conclusion, until new agents are developed against
resistant microorganisms, the only alternative therapy
option appears to be the use of combination therapies (26).
According to our study, the combination of MEM with
CST or TGC offers an alternative option by increasing the
activity of MEM when treating CR Acinetobacter strains.
Prospective clinical comparison studies are needed to
understand the potential benefits of combination therapies
against monotherapy in treating CR Gram-negative
bacteria infections.
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